Mesenchymal stem cells: a future experimental exploration for recession of diabetic nephropathy.
Mesenchymal stem cells: a future experimental exploration for recession of diabetic nephropathy.
复制标题
DOI：
10.1080/0886022x.2016.1244080
复制
发表时间：
2017-11
期刊：
影响因子：
3
通讯作者：
Ahmed HH
中科院分区：
文献类型：
--
作者：
Hamza AH;Al-Bishri WM;Damiati LA;Ahmed HH
背景资料：干细胞治疗的进展为受损器官和组织的修复提供了一种创新的方法，并显示出巨大的潜力。本研究旨在探讨骨髓间充质干细胞（BM-MSCs）抑制糖尿病和实验性糖尿病肾病的作用机制。研究方法：为了实现这一目标，通过大量的生物化学和分子遗传学分析研究了接受MSC治疗的糖尿病和糖尿病肾病受试者组。结果如下：结果显示，相对于对照组，用骨髓间充质干细胞输注的干细胞治疗的糖尿病和糖尿病肾病组的大鼠在其胰岛素、葡萄糖、血红素加氧酶-1（HO-1）血清和晚期糖基化终产物（AGEP）水平上显示出显著逆转。此外，BM-MSC治疗也被发现对肾功能有明确的积极影响。此外，它还与某些生长因子（即成纤维细胞生长因子（FGF）、血小板衍生生长因子（PDGF）和转化生长因子-β（TGF-β））的可用性显著降低相对应。BM-MSC治疗还提高了肾组织中单核细胞趋化因子-1（MCP-1）和白细胞介素-8（IL-8）基因的表达水平。最后，治疗恢复了肾脏和胰腺的组织结构，组织病理学分析证明了这一结果。这些结果与生化和分子遗传学分析结果基本一致。结论：骨髓间充质干细胞治疗糖尿病及糖尿病肾病疗效确切。
Background: The progresses made in stem cell therapy offer an innovative approach and exhibit great potential for the repair of damaged organs and tissues. This study was conducted with a view to find the mechanisms responsible for the effectiveness of bone marrow-derived mesenchymal stem cells (BM-MSCs) in the suppression of diabetes and experimentally-induced diabetic nephropathy. Methods: To realize this objective, diabetic and diabetic nephropathy subject groups that underwent MSC treatment were studied through numerous biochemistry and molecular genetics analyses. Results: The findings show that, relative to the control groups, the rats in the diabetic and diabetic nephropathy groups treated with stem cells infused with BM-MSCs showed a significant reversal in the levels of their insulin, glucose, heme-oxygenase-1 (HO-1) serum, and advanced glycation end product (AGEP). Moreover, BM-MSC therapy was also found to have a definite positive effect on the kidney functions. In addition, it also corresponded with a significant decrease in the availability of certain growth factors, namely the fibroblast growth factor (FGF), the platelet-derived growth factor (PDGF), and the transforming growth factor-β (TGF-β). BM-MSC treatment also improved the levels of expression of monocyte chemoatractant-1 (MCP-1) and interleukin-8 (IL-8) genes within kidney tissues. Lastly, the treatment recovered the organizational structure of the kidney and pancreas, a result demonstrated by a histopathological analysis. These results greatly coincide with those obtained through the biochemistry and molecular genetics analyses. Conclusion: Treatment using BM-MSCs is determined to be definitely effective in cases of diabetes and diabetic nephropathy.